SAN FRANCISCO, Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D., as chief operating officer, effective November 13, 2023. Dr. Sholehvar is a healthcare business leader with a 25-year track record of successfully solving complex problems and leading business transformations, addressing regulatory challenges and developing new product and growth strategies..

2023年10月19日，旧金山/PRNewswire/-领先的医学遗传学公司Invitae（NYSE:NVTA）今天宣布任命退伍军人医疗保健领导者David Sholehvar，M.D。为首席运营官，自2023年11月13日起生效。Sholehvar博士是医疗保健业务领导者，拥有成功解决复杂问题和领导业务转型，应对监管挑战以及开发新产品和增长战略的25年记录。。

'I'm excited to welcome Dr. Sholehvar to the Invitae leadership team. His extensive general management experience in both large and small healthcare companies, as well as global functional leadership in sales, marketing, strategy and innovation will be an enormous benefit to Invitae as we continue our focus on operational excellence and innovation,' said Ken Knight, president and chief executive officer of Invitae..

“我很高兴欢迎Sholehvar博士加入Invitae领导团队。他在大小医疗保健公司拥有广泛的一般管理经验，以及在销售，营销，战略和创新方面的全球功能领导力，将对Invitae产生巨大的好处，因为我们继续关注运营卓越和创新，'Ken Knight说，Invitae总裁兼首席执行官。。

Dr. Sholehvar most recently held the role of president, clinical services division, at NeoGenomics Inc., an oncology diagnostics company, where he was responsible for the commercial and strategic growth of the clinical services division. From 2017 to 2020, Dr. Sholehvar served as chief executive officer for Dynex Technologies, Inc., a manufacturer of laboratory instruments and associated consumables and accessories, where his focus was transforming Dynex's business model..

Sholehvar博士最近在肿瘤诊断公司NeoGenomics Inc.担任临床服务部总裁，负责临床服务部的商业和战略发展。从2017年到2020年，Sholehvar博士担任Dynex Technologies，Inc。的首席执行官，Dynex Technologies，Inc。是一家实验室仪器及相关耗材和配件的制造商，他的重点是改变Dynex的商业模式。。

Prior to Dynex, Dr. Sholehvar spent four years with Quest Diagnostics, a Fortune 500 company and leading provider of diagnostic information services, serving as vice president of Quest's largest sales region from 2014 to 2017, and general manager of infectious disease and immunology from 2013 to 2014.

在Dynex之前，Sholehvar博士在Quest Diagnostics公司工作了四年，Quest Diagnostics是一家财富500强公司和领先的诊断信息服务提供商，2014年至2017年担任Quest最大销售区域的副总裁，并担任传染病和免疫学总经理。2013年至2014年。

Dr. Sholehvar has also served as vice president for the Americas and EMEA for Ortho Clinical Diagnostics, a former Johnson & Johnson company, and general manager for Cellular Technologies, Inc., a former Johnson & Johnson company, where he oversaw Johnson & Johnson subsidiaries including Veridex, LLC, a startup focused on the detection of circulating tumor cells.

Sholehvar博士还曾担任美洲副总裁和EMEA的前强生公司Ortho Clinical Diagnostics的副总裁，以及前强生公司Cellular Technologies，Inc.的总经理，负责监督强生子公司。Veridex，LLC是一家专注于检测循环肿瘤细胞的初创企业。

Dr. Sholehvar received a bachelor's degree from the University of Pittsburgh, an M.D. from Thomas Jefferson University and a master of business administration from the University of Pittsburgh Katz School of Business..

Sholehvar博士获得匹兹堡大学学士学位，托马斯·杰斐逊大学医学博士学位和匹兹堡大学卡茨商学院商业管理硕士学位。。

'I'm looking forward to joining the Invitae team and using my healthcare leadership experience to focus on operational excellence in support of Invitae's mission to make genetic information part of mainstream medicine,' said Dr. Sholehvar.

Sholehvar博士说：“我期待加入Invitae团队，并利用我的医疗保健领导经验专注于卓越运营，以支持Invitae将遗传信息作为主流医学一部分的使命。”。

Inducement GrantPursuant to his hiring as Invitae's chief operating officer, Invitae is granting 850,000 restricted stock units ('RSUs') to Dr. Sholehvar under Invitae's 2015 Stock Incentive Plan (the '2015 Plan'), which will be amended and restated to add 850,000 shares of Invitae common stock to a pool of shares under the 2015 Plan which is to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ('Rule 303A.08').

INDUCTION授予他作为Invitae首席运营官的招聘，Invitae根据Invitae的2015年股票激励计划（'2015计划'）向Sholehvar博士授予850000个限制性股票单位（'RSU'），将根据2015年计划对85万股Invitae普通股进行修订和重申，该计划将根据纽约证券交易所规则303A.08（“规则303A”）专门用于授予诱导奖。.08'）。

The RSUs, which are subject to approval by Invitae's Board of Directors, are being granted as an inducement material to Dr. Sholehvar's agreement to be employed with Invitae in reliance on the employment inducement exemption under Rule 303A.08. One-third of the RSUs will vest on each of the first three anniversaries of November 15, 2023, subject to Dr.

RSU经Invitae董事会批准，作为Sholehvar博士同意与Invitae合作的诱导材料，根据规则303A.08的就业诱导豁免，被授予RSU。三分之一的RSU将在2023年11月15日的前三个anniversaries中的每一个上投资，受Dr。

Sholehvar's continued service as an employee of Invitae through the applicable vesting dates. The grant of the RSUs is subject to the terms and conditions of the 2015 Plan and the applicable form of stock award agreement..

Sholehvar在适用的调查日期继续担任Invitae的员工。RSUs的赠款受2015年计划的条款和条件以及适用的股票奖励协议形式的约束。。

About InvitaeInvitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families.

关于InvitaeInvitae（纽约州：NVTA）是一家领先的医学遗传学公司，受到数百万患者及其提供者的信任，可以使用数字技术提供及时的遗传信息。我们的目标是提供准确和可行的答案，以加强个人及其家庭的医疗决策。

Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people..

Invitae的遗传学专家对数据和研究采取严格的方法，作为他们将全面的遗传信息纳入主流医学以改善数十亿人医疗保健的使命的基础。。

To learn more, visit invitae.com and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae.

要了解更多信息，请访问invitae.com并关注Twitter，Instagram，Facebook和LinkedIn@invitae上的更新。

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the expected benefits Dr. Sholehvar will bring to the company. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance.

安全港声明本新闻稿包含1995年“私人证券诉讼改革法案”含义内的前瞻性声明，包括与Sholehvar博士将为公司带来的预期利益相关的声明。前瞻性陈述可能会导致实际结果出现重大差异的风险和不确定性，报告的结果不应被视为未来业绩的指标。

These risks and uncertainties include, but are not limited to: the company's ability to grow its business in a cost-efficient manner; the company's history of losses; the company's ability to maintain important customer relationships; the company's ability to compete; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.

这些风险和不确定性包括但不限于：公司以具有成本效益的方式发展业务的能力；公司的损失历史；公司维护重要客户关系的能力；公司的竞争能力；与诉讼有关的风险；公司能够使用快速变化的遗传数据准确，一致地解释测试结果；安全违规，数据丢失和其他中断；适用于公司业务的法律法规；以及本公司向证券交易委员会提交的其他风险，包括本公司截至2023年6月30日止季度10-Q表格季度报告中提出的风险。

These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements..

这些前瞻性声明仅在本协议签署之日起生效，Invitae Corporation不承担更新这些前瞻性声明的任何义务。。

Invitae Contacts:

_其他组织者

Investor RelationsHoki Luk[email protected]

投资者关系Shoki Luk[电子邮件保护]

Public RelationsAmy Hadsock[email protected]

公共关系Samy Hadsock[电子邮件保护]

SOURCE Invitae Corporation

来源Invitae公司